leadf
logo-loader
viewXPhyto Therapeutics Corp.

XPhyto Therapeutics subsidiary Vektor Pharma to develop psilocybin active pharmaceutical ingredients with German university

Germany-based Vektor will exclusively develop a proprietary process for industrial production of psilocybin

XPhyto Therapeutics Corp. -
XPhyto is currently focused on securing industrial-scale production of psychedelic APIs and standardizing drug formulations

XPhyto Therapeutics Corp (CSE:XPHY) (OTCMKTS:XPHYF) (FRA:4XT) said Tuesday that its German subsidiary Vektor Pharma TF GmbH will start to develop a process to manufacture psilocybin as a certified active pharmaceutical ingredient (API). 

The subsidiary inked a research agreement with a leading German university that will see Vektor exclusively develop a proprietary process for industrial production of psilocybin, Vancouver-based XPhyto told investors. 

In a statement, XPhyto said it is currently focused on securing industrial-scale production of psychedelic APIs and standardizing drug formulations. A biotechnology production program started last month and is expected to finish around September 2021. 

READ: XPhyto touts rapid 25-minute RT-PCR lab test for coronavirus detection

The firm said it had identified multiple psychedelic compounds that could be effective in treating mental health conditions.

"Psychedelic agents are a promising new class of therapeutic drug,” XPhyto CEO Hugh Rogers told shareholders.

“We see a natural opportunity to apply XPhyto's drug formulation expertise and Vektor's proven drug delivery platforms to these emerging APIs. Our goal is the development of precise and predictable psychedelic drug formulations for clinical study and therapeutic use."

Psilocybin was recently designated as a "breakthrough therapy" for the treatment of severe and treatment-resistant depression by the US Food and Drug Administration. Allied Market Research estimates the global antidepressant drugs market could reach nearly US$16 billion by 2023, with an estimated compound annual growth rate of 2.1% from 2017 to 2023.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: XPhyto Therapeutics Corp.

Price: 2.26 CAD

CSE:XPHY
Market: CSE
Market Cap: $137 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

XPhyto Therapeutics continues to move toward commercialization of their...

XPhyto Therapeutics (CSE: XPHY- OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to provide an update on their plans to go to market in Europe with their testing program for the COVID-19 Rogers talks about where that program is AT and also about their drug delivery platform...

on 4/11/20

2 min read